Myriad Shares Recover after Medicare Contractors Confirm Error on BRCA1/2 CPT Code Price | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics' stock rebounded today after two Medicare contractors acknowledged an error in the reimbursement rate for Myriad's BRACAnalysis test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.